Donate

Metabolic Syndrome in Men with Castration-Resistant Prostate Cancer Treated with Abiraterone Affects Their Survival

Yesterday’s post was about the increased risks of developing diabetes faced by men who are on hormone therapy. This study, as well as most others about this topic has looked at the first levels of hormone therapy (ADT) using the traditional drugs like Zoladex, Trelstar, Firmagon, and Lupron. We know very little about the influence [...]

Hormone Therapy (ADT) Increases By 60% A Man’s Risk of Developing Diabetes

According to a recent study published in the Journal of Urology, men with localized prostate cancer on hormone therapy (ADT) have a significant increase in their risk for developing diabetes. In this retrospective study of 12,191 men with localized prostate cancer who did not have diabetes were followed once they went on ADT. It was [...]

The Positive Effects of Endurance Training for Men with Advanced Prostate Cancer On ADT

All of us on androgen deprivation therapy (ADT) know that without testosterone our bodies change and we will develop insulin resistance, the precursor to diabetes. In a just very small, just published study investigators examined if endurance training would improve insulin sensitivity and body composition in men being treated with ADT for their advanced prostate [...]

US FDA Reviewing the Safety of LHRH Agonists – ADT with Advanced Prostate Cancer

Hormone therapy (ADT), using luteinizing hormone releasing hormone (LHRH) agonists or gonadatropin releasing hormone or GnRH agonists (Lupron, Zoladex, Trelstar, Viadur, Vantas, Eligard and Synarel ) have been known to have many side effects, some severe and potentially life threatening. Many of us believe that ADT is associated with cardiovascular disease and diabetes along with [...]

The Effect of Diabetes on Prostate Cancer Mortality

Concerned that your diabetes could making you more vulnerable to dying from prostate cancer? Yes, diabetes sufferers should be concerned about a potential shorter life span, but not as of a result of prostate cancer (CaP). In the Journal of Clinical Oncology (September 10, 2008), Dr. Matthew Smith and his colleagues reported on the association [...]

Go to Top